



## Systematic Identification of Signal-Activated Stochastic Gene Regulation

Gregor Neuert *et al.*  
*Science* **339**, 584 (2013);  
DOI: 10.1126/science.1231456

*This copy is for your personal, non-commercial use only.*

If you wish to distribute this article to others, you can order high-quality copies for your colleagues, clients, or customers by [clicking here](#).

Permission to republish or repurpose articles or portions of articles can be obtained by following the guidelines [here](#).

**The following resources related to this article are available online at [www.sciencemag.org](http://www.sciencemag.org) (this information is current as of January 31, 2013):**

**Updated information and services**, including high-resolution figures, can be found in the online version of this article at:

<http://www.sciencemag.org/content/339/6119/584.full.html>

**Supporting Online Material** can be found at:

<http://www.sciencemag.org/content/suppl/2013/01/30/339.6119.584.DC1.html>

This article **cites 35 articles**, 13 of which can be accessed free:

<http://www.sciencemag.org/content/339/6119/584.full.html#ref-list-1>

This article appears in the following **subject collections**:

Molecular Biology

[http://www.sciencemag.org/cgi/collection/molec\\_biol](http://www.sciencemag.org/cgi/collection/molec_biol)

that has undergone EMT into a cluster of such cells or, alternatively, from the mesenchymal transformation of preexisting CTC clusters within the bloodstream. The proposal that mesenchymal transformation of epithelial cells is mediated by TGF- $\beta$  released from platelets (15) is supported by our observation of strong TGF- $\beta$  signatures in mesenchymal CTC clusters, many of which carry attached platelets. Collective migration of grouped cells that maintain their cell-cell and cell-matrix connections has been implicated in cancer metastasis (26, 27), and may involve increased survival signals as CTC clusters circulate in the blood (17, 28, 29). The clinical importance of EMT as a potential biomarker of therapeutic resistance and as a potential drug target in breast cancer warrants further investigation.

#### References and Notes

1. D. X. Nguyen, P. D. Bos, J. Massagué, *Nat. Rev. Cancer* **9**, 274 (2009).
2. J. P. Thiery, *Nat. Rev. Cancer* **2**, 442 (2002).
3. R. Kalluri, R. A. Weinberg, *J. Clin. Invest.* **119**, 1420 (2009).
4. T. Brabletz, *Nat. Rev. Cancer* **12**, 425 (2012).
5. H. Ledford, *Nature* **472**, 273 (2011).

6. K. Pantel, R. H. Brakenhoff, B. Brandt, *Nat. Rev. Cancer* **8**, 329 (2008).
7. M. Yu, S. Stott, M. Toner, S. Maheswaran, D. A. Haber, *J. Cell Biol.* **192**, 373 (2011).
8. H. Jeong, Y. J. Ryu, J. An, Y. Lee, A. Kim, *Histopathology* **60**, E87 (2012).
9. Z. Jiang *et al.*, *Cell Cycle* **10**, 1563 (2011).
10. S. L. Stott *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **107**, 18392 (2010).
11. M. Yu *et al.*, *Genes Dev.* **23**, 1737 (2009).
12. R. E. Payne *et al.*, *Br. J. Cancer* **106**, 1790 (2012).
13. M. G. Krebs *et al.*, *J. Thorac. Oncol.* **7**, 306 (2012).
14. E. H. Cho *et al.*, *Phys. Biol.* **9**, 016001 (2012).
15. M. Labelle, S. Begum, R. O. Hynes, *Cancer Cell* **20**, 576 (2011).
16. F. Ozsolak *et al.*, *Nat. Methods* **7**, 619 (2010).
17. M. Yu *et al.*, *Nature* **487**, 510 (2012).
18. J. H. Taube *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **107**, 15449 (2010).
19. K. Polyak, R. A. Weinberg, *Nat. Rev. Cancer* **9**, 265 (2009).
20. N. Bloustain-Qimron *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **105**, 14076 (2008).
21. Y. Hüsemann *et al.*, *Cancer Cell* **13**, 58 (2008).
22. A. D. Rhim *et al.*, *Cell* **148**, 349 (2012).
23. A. J. Armstrong *et al.*, *Mol. Cancer Res.* **9**, 997 (2011).
24. A. Lecharpentier *et al.*, *Br. J. Cancer* **105**, 1338 (2011).
25. C. V. Pecot *et al.*, *Cancer Discov.* **1**, 580 (2011).
26. O. Iliina, P. Friedl, *J. Cell Sci.* **122**, 3203 (2009).
27. D. G. Duda *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **107**, 21677 (2010).
28. Y. N. Kim, K. H. Koo, J. Y. Sung, U. J. Yun, H. Kim, *Int. J. Cell Biol.* **2012**, 306879 (2012).
29. J. M. Hou *et al.*, *J. Clin. Oncol.* **30**, 525 (2012).

**Acknowledgments:** We are grateful to all the patients who participated in this study; we thank D. Juric, C. Koris, and the Massachusetts General Hospital (MGH) clinical research coordinators for help with clinical studies; A. Gilman, B. Brannigan, and M. Zeinali for technical support; F. Ozsolak and P. Milos (Helicos) for RNA sequencing; A. Forrest-Hay and Q. Nguyen (Affymetrix) for RNA-ISH reagents; L. Libby for mouse studies; and J. Walsh for expertise with microscopy. This work was supported by grants from the Breast Cancer Research Foundation (D.A.H.), Stand Up To Cancer (D.A.H., M.T., and S.M.), Susan G. Komen for the Cure KG090412 (S.M.), NIBIB EB008047 (M.T., D.A.H.), NCI CA129933 (D.A.H.), the National Cancer Institute–MGH Federal Share Program (S.M.), and the Howard Hughes Medical Institute (M.Y. and D.A.H.). The MGH and M.T. have filed a patent for the HB (Herringbone) microchip (U.S. patent 09816815.4). Sequencing data have been deposited in the Gene Expression Omnibus database (accession no. GSE41245).

#### Supplementary Materials

www.sciencemag.org/cgi/content/full/339/6119/580/DC1  
Materials and Methods  
Figs. S1 to S7  
Tables S1 to S7  
References (30–36)  
Movie S1

7 August 2012; accepted 6 December 2012  
10.1126/science.1228522

## Systematic Identification of Signal-Activated Stochastic Gene Regulation

Gregor Neuert,<sup>1,2\*</sup> Brian Munsky,<sup>3\*</sup> Rui Zhen Tan,<sup>1,5,6</sup> Leonid Teytelman,<sup>1</sup> Mustafa Khammash,<sup>4,7†</sup> Alexander van Oudenaarden<sup>1,8,††</sup>

Although much has been done to elucidate the biochemistry of signal transduction and gene regulatory pathways, it remains difficult to understand or predict quantitative responses. We integrate single-cell experiments with stochastic analyses, to identify predictive models of transcriptional dynamics for the osmotic stress response pathway in *Saccharomyces cerevisiae*. We generate models with varying complexity and use parameter estimation and cross-validation analyses to select the most predictive model. This model yields insight into several dynamical features, including multistep regulation and switchlike activation for several osmosensitive genes. Furthermore, the model correctly predicts the transcriptional dynamics of cells in response to different environmental and genetic perturbations. Because our approach is general, it should facilitate a predictive understanding for signal-activated transcription of other genes in other pathways or organisms.

A central goal of systems biology is to understand and predict the complex, stochastic dynamics of gene regulation (1–3). Although biochemical studies have identified many regulatory proteins in these processes, this typically does not enable construction of quantitatively predictive models of transcriptional dynamics. One challenge lies in the fact that gene regulation is a dynamic multistate process with largely unknown reaction rates. For example, a two-state system may represent closed and open chromatin (4–6) or the presence or absence of a transcription factor (7–9). Including more states or regulatory reactions results in a combinatorial increase in the

number of possible model structures (10) and leads to a complicated trade-off between overfitting and predictive power.

We propose a data-driven comprehensive approach to identify and validate predictive, quantitative models of transcriptional dynamics through the integration of single-cell experiments and discrete stochastic analyses within a system identification framework. We apply this approach to the well-characterized high-osmolarity glycerol (HOG) mitogen-activated protein kinase (MAPK) pathway in *Saccharomyces cerevisiae* and focus on the regulation of *STL1*, *CTT1*, and *HSP12* (11, 12) genes. Upon osmotic shock, the Hog1p kinase

quickly enters the nucleus (Fig. 1A, and figs. S2 to S4, and S6) (13–16) and activates *STL1*, *CTT1*, and *HSP12* gene expression (figs. S6 and S9) (17). We find that the Hog1p translocation dynamics is homogeneous (14, 15, 17), yet downstream gene activation is heterogeneous among cells (17). To quantify *STL1* expression directly, we developed a single-molecule fluorescent in situ hybridization (smFISH) (18, 19, 20) assay, which captures the stochastic nature of mRNA transcription with high temporal and single-molecule resolution (Fig. 1B) (21, 22, 23).

In addition to the kinase Hog1p, we consider the effects of the transcription factor Hot1p and the chromatin modifiers Arp8p and Gcn5p that modulate *STL1* transcription (17, 24). For this system, we seek to find and validate a model that predicts the system's dynamic mRNA expression

<sup>1</sup>Departments of Physics and Biology and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. <sup>2</sup>Department of Molecular Physiology and Biophysics, School of Medicine, Vanderbilt University, Nashville, TN 37232, USA. <sup>3</sup>Center for Nonlinear Studies and the Information Sciences Group, Los Alamos National Laboratory, Los Alamos, NM 87545, USA. <sup>4</sup>Department of Biosystems Science and Engineering, ETH-Zuerich, 4058 Basel, Switzerland. <sup>5</sup>Bioinformatics Institute, A\*STAR, Singapore 138671, Singapore. <sup>6</sup>Harvard University Graduate Biophysics Program, Harvard Medical School, Boston, MA 02115, USA. <sup>7</sup>Center for Control, Dynamical Systems and Computation and Department of Mechanical Engineering, University of California, Santa Barbara, CA 93106, USA. <sup>8</sup>Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center Utrecht, Uppsalalaan 8, 3584 CT, Utrecht, Netherlands.

\*These authors contributed equally to this work.

†Co-senior authors.

††To whom correspondence should be addressed. E-mail: a.vanoudenaarden@hubrecht.eu


for several genes (*STL1*, *CTT1*, and *HSP12*) in response to environmental and genetic perturbations. We propose a range of model structures, each with a discrete number of states,  $\{S_1, S_2, \dots, S_N\}$  (Fig. 2A). Each haploid cell occupies one state at a time, and transitions among states are discrete, stochastic events. At least two states are required to explain bimodality, but additional states allow for more complex mechanisms, such as chromatin remodeling or transcription factor binding or release (7–9, 17). Because activated mRNA transcription and degradation rates are constant throughout different conditions (fig. S5), only transition rates can be variable and are as-

sumed to be constant or linearly dependent on the kinase. After identifying the model structure and Hog1p dependency, we validate the model structure for several mutants and different Hog1p-dependent genes.


To choose the best number of states needed to match every state transition rate to be Hog1p-dependent. For two-, three-, four-, and five-state model structures with any parameter set, we use the finite state projection (FSP) approach (25) to formulate a finite set of linear ordinary differential equations that predicts the time-varying probability distributions. We adjust the model parameters

until the FSP analysis fits the bimodal mRNA distributions at all times (26). As expected, the fit improves as the model complexity increases (Fig. 2B, red line, and fig. S11). However, increased complexity leads to greater parametric uncertainty and may diminish predictive power. Applying cross-validation analyses to replicate experiments at 0.4 M NaCl (27), we score all models according to their estimated predictive power (Fig. 2B, blue line). This prediction estimate is validated with additional experiments conducted at 0.2 M NaCl, and we find that cross-validation provides an excellent estimate of predictive power (Fig. 2B, compare blue and green lines, and figs. S11 and S12). We find that the two- and three-state models are too simple, whereas the more complex five-state model structure is prone to overfitting (Fig. 2B and figs. S11 and S12).


We now concentrate on the four-state model structures and determine which reactions depend upon Hog1p. To identify a Hog1p-model structure with enough flexibility to match the data while avoiding overfitting, we allow one or two Hog1p dependencies. We then rank the corresponding maximum likelihoods and cross-validate the top ranked Hog1p-model structures. The fit improves with increasing complexity (Fig. 2B, red line, and fig. S11), while constraining the number of Hog1p dependencies reduces uncertainty (Fig. 2B and fig. S11). One notable feature of the identified model structure and its corresponding parameters is that in the absence of Hog1p, a fast reaction from  $S_2 \rightarrow S_1$  keeps all cells in the inactive  $S_1$  state (fig. S8, red




**Fig. 1.** Quantitative analysis of single-cell stochastic gene regulation. **(A)** Schematic of a generic signaling cascade in which a kinase enters the nucleus and interacts with transcription factors (TF) and chromatin modifiers (CM) to regulate gene expression. **(B)** Rapid, stochastic, and bimodal activation of endogenous *STL1* mRNA expression is detected with single-molecule RNA-FISH [yeast cell: gray circle; DAPI (4',6-diamidino-2-phenylindole)-stained nucleus: blue; *STL1* mRNA: green dots]. Scale bar: 2  $\mu$ m.



**Fig. 2.** Identifying a maximally predictive model structure. **(A)** Two- and multistate model structures that allow for kinase, transcription factor, and chromatin modifier-dependent activation of gene expression. **(B)** Relative likelihoods of best fit for different model structures at 0.4 M NaCl (red, left axis) and the resulting predictions at 0.2 M NaCl (green, right axis). Cross-validation at 0.4 M NaCl (27) is used to quantify predictive uncertainty (gray region, left axis) and yields excellent a priori knowledge of predictive power (compare blue and green lines). **(C)** mRNA expression distributions at two NaCl concentrations (black and blue lines) and best fit at 0.4 M (red line) and the corresponding prediction at 0.2 M NaCl (green line). The fit and predictions correspond to the four-state structure with one Hog1p dependency identified at 0.4 M NaCl in (fig. S7). The black arrow indicates the similar mRNA expression levels after an osmotic shock of 0.2 and 0.4 M NaCl. The purple star indicates the time point of gene expression deactivation.






**Fig. 3. Model structure validation. (A)** Combined fit of the model structure identified (fig. S7) to different genetic mutations affecting *STL1* expression at 0.4 M NaCl: wild-type (WT) (red), Hot1p 5× (blue), *arp8*Δ (black), and *gcn5*Δ (green). **(B)** Model prediction of *CTT1* (cyan) and *HSP12* (magenta) expression at 0.2 M NaCl. **(C)** Model prediction for *HSP12* expression at 0.4 M in the *arp8*Δ strain.

line). When Hog1p exceeds a certain threshold, the gene can transition among the active  $S_2$ ,  $S_3$ , and  $S_4$  states (fig. S8, blue, green, and black lines). Our final model captures all qualitative and quantitative features of *STL1* mRNA expression dynamics after a 0.4 M NaCl osmotic shock (Fig. 2C, top). These features include a constant time delay,  $t_0$ , between Hog1p translocation and mRNA expression; slow activation of gene expression; transient bimodality in RNA populations; conserved maximal mRNA expression between different conditions; and Hog1p-dependent modulation of gene expression duration. In addition, the model makes the best predictions for the mRNA expression after osmotic shock with 0.2 M NaCl (Fig. 2C, bottom).

To test the generality of this model's predictive power, we collect new data sets at 0.4 M NaCl for several different mutant strains and for different Hog1p-activated genes. The different mutant strains include a fivefold Hot1p-overexpression strain and gene knockouts of the chromatin modifiers *ARP8* or *GCN5*. We also consider two additional stress response genes: *CTT1* and *HSP12*. The model identified above fits equally well to the mRNA expression dynamics for *STL1* in the Hot1p-overexpression strain as well as the *arp8*Δ and *gcn5*Δ mutants (Fig. 3A and figs. S15, S18, and S19). The same structure also fits the *CTT1* and *HSP12* mRNA expression dynamics (figs. S9, S15, S18, and S19) with relatively few parameter changes between the different genes and mutations (table S2) (27). The resulting model makes excellent predictions for the dynamics of *CTT1* and *HSP12* mRNA



**Fig. 4. Relating model structure to biological function. (A)** Mutant and gene-specific rate changes relative to *STL1*. **(B)** Final model, in which Hog1p, Hot1p, Gcn5p, and Arp8p regulate transitions between states  $S_1$  and  $S_2$ .

expression at 0.2 M NaCl (Fig. 3, B and C, and figs. S16, S18, and S19). Combining the relative changes in the rates measured for *STL1* in the mutant *ARP8* strain with the rate changes for the *CTT1* and *HSP12* expression measured in wild-type strain results in a very good prediction of the *CTT1* and *HSP12* mRNA expression in the *ARP8* mutant strain (Fig. 3C and figs. S17 to S19) (27).

Having determined that the model structure identified above can fit and predict *STL1*, *CTT1*, and *HSP12* mRNA expression dynamics in different mutant strains, we examine which rates vary most for each mutant and gene in comparison to wild-type *STL1* (Fig. 4A and table S2). The most variable rates between different mutations are the  $k_{12}$  and  $k_{21}$  transition rates, which indicate

that Hot1p, Gcn5p, and Arp8p all modulate the transition rates into and out of the  $S_1$  state but result in different Hog1p-activation and -deactivation thresholds (fig. S10). Other transition rates are affected to a much lower degree.

The identified model structure and parameters quantitatively capture and/or predict all of the observed experimental data (Figs. 2 to 4 and figs. S15 to S19). The model also yields several qualitative and quantitative insights, including (i) a switchlike mechanism that activates each gene and stabilizes its activity when Hog1p exceeds a gene-specific threshold and (ii) gene-specific production and degradation rates that are independent of the Hog1p-kinase dynamics. The four-state model structure is essential to explain the temporal dynamics in gene expression observed in

all of the experiments. This structure describes an Off state,  $S_1$ , which is the default state in the absence of osmotic shock, and three On states with different transcription rates and reaction rates between the states. Activation occurs when nuclear Hog1p represses the deactivation rate,  $k_{21}$ , subject to the interplay of gene- and mutant-specific (de)activation thresholds (fig. S10 and table S2). This interplay provides the main knob by which the duration of mRNA expression is finely tuned in response to different environmental conditions (e.g., different salt concentrations) or to different genetic mutations.

In this study, we have identified a single quantitative model to understand and predict *STL1*, *CTT1*, and *HSP12* gene expression dynamics in response to various environmental and genetic perturbations. We generated a large range of possible model structures and developed a dynamic single-cell assay with which to discriminate among these model structures. We combined this experimental assay with discrete stochastic analyses and parameter identification approaches. Our cross-validation analyses systematically eliminated oversimplified and overcomplex model structures. We eventually selected the model structure and parameters for a single best model to predict *STL1*, *CTT1*, and *HSP12* dynamics. Furthermore, the identified model provides detailed insight into the biophysical dynamics of signal-activated gene regulation. Because the presented experimental and computational tools are applicable to any gene or signaling pathway, this

integrated identification approach can lead to insights into complex cellular networks for other organisms.

#### References and Notes

- H. Y. Chuang, M. Hofree, T. Ideker, *Annu. Rev. Cell Dev. Biol.* **26**, 721 (2010).
- M. A. Schwartz, H. D. Madhani, *Annu. Rev. Genet.* **38**, 725 (2004).
- V. M. Weake, J. L. Workman, *Nat. Rev. Genet.* **11**, 426 (2010).
- A. Raj, C. S. Peskin, D. Tranchina, D. Y. Vargas, S. Tyagi, *PLoS Biol.* **4**, e309 (2006).
- J. M. Raser, E. K. O'Shea, *Science* **304**, 1811 (2004).
- M. S. Ko, H. Nakauchi, N. Takahashi, *EMBO J.* **9**, 2835 (1990).
- C. Cheung, P. Cramer, *Nature* **471**, 249 (2011).
- C. Hodges, L. Bintu, L. Lubkowska, M. Kashlev, C. Bustamante, *Science* **325**, 626 (2009).
- H. Boeger, J. Griesenbeck, R. D. Kornberg, *Cell* **133**, 716 (2008).
- W. Ma, A. Trusina, H. El-Samad, W. A. Lim, C. Tang, *Cell* **138**, 760 (2009).
- C. Ferreira *et al.*, *Mol. Biol. Cell* **16**, 2068 (2005).
- S. Hohmann, *Microbiol. Mol. Biol. Rev.* **66**, 300 (2002).
- P. Ferrigno, F. Posas, D. Koepf, H. Saito, P. A. Silver, *EMBO J.* **17**, 5606 (1998).
- P. Hersen, M. N. McClean, L. Mahadevan, S. Ramanathan, *Proc. Natl. Acad. Sci. U.S.A.* **105**, 7165 (2008).
- J. T. Mettetal, D. Muzzey, C. Gómez-Urbe, A. van Oudenaarden, *Science* **319**, 482 (2008).
- D. Muzzey, C. A. Gómez-Urbe, J. T. Mettetal, A. van Oudenaarden, *Cell* **138**, 160 (2009).
- S. Pelet *et al.*, *Science* **332**, 732 (2011).
- A. Raj, P. van den Bogaard, S. A. Rifkin, A. van Oudenaarden, S. Tyagi, *Nat. Methods* **5**, 877 (2008).
- A. M. Femino, F. S. Fay, K. Fogarty, R. H. Singer, *Science* **280**, 585 (1998).
- S. L. Bumgarner *et al.*, *Mol. Cell* **45**, 470 (2012).
- J. M. Pedraza, J. Paulsson, *Science* **319**, 339 (2008).

- B. Munsky, B. Trinh, M. Khammash, *Mol. Syst. Biol.* **5**, 318 (2009).
- B. Munsky, G. Neuert, A. van Oudenaarden, *Science* **336**, 183 (2012).
- P. M. Alepuz, E. de Nadal, M. Zapater, G. Ammerer, F. Posas, *EMBO J.* **22**, 2433 (2003).
- B. Munsky, M. Khammash, *J. Chem. Phys.* **124**, 044104 (2006).
- Using full mRNA distributions for fitting yields substantially improved predictions (fig. S13) compared to fitting with the procedure in (28) that uses only means and variances.
- Materials and methods are available as supplementary materials on Science Online.
- C. Zechner *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **109**, 8340 (2012).

**Acknowledgments:** This work was funded by the NSF (ECCS-0835847) and Human Frontier Science Program (RGP0061/2011) to M.K.; the NSF (ECCS-0835623), National Institutes of Health—National Cancer Institute Physical Sciences Oncology Center at Massachusetts Institute of Technology (U54CA143874), and an NIH Pioneer award (1DP10D003936) to A.v.O.; Los Alamos National Laboratory—Laboratory Directed Research and Development to B.M.; the Deutsche Forschungsgemeinschaft (Forschungs Stipendium) to G.N.; and the A\*STAR program, Singapore, to R.Z.T. We thank F. van Werven for the yeast crosses and N. Hengartner, B. Pando, S. Klemm, J. van Zon, and M. Wall for discussions on the model. We also thank M. Bienko, N. Crosetto, C. Engert, S. Itzkovitz, J. P. Junker, S. Klemm, S. Semrau, J. van Zon, and H. Youk for comments on the manuscript.

#### Supplementary Materials

www.sciencemag.org/cgi/content/full/339/6119/584/DC1  
Materials and Methods  
Figs. S1 to S19  
Tables S1 and S2  
References (29–38)

12 October 2012; accepted 10 December 2012  
10.1126/science.1231456

## Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents

Andrea E. Prota,<sup>1</sup> Katja Bargsten,<sup>1</sup> Didier Zurwerra,<sup>2</sup> Jessica J. Field,<sup>3</sup> José Fernando Díaz,<sup>4</sup> Karl-Heinz Altmann,<sup>2</sup> Michel O. Steinmetz<sup>1\*</sup>

Microtubule-stabilizing agents (MSAs) are efficacious chemotherapeutic drugs widely used for the treatment of cancer. Despite the importance of MSAs for medical applications and basic research, their molecular mechanisms of action on tubulin and microtubules remain elusive. We determined high-resolution crystal structures of  $\alpha\beta$ -tubulin in complex with two unrelated MSAs, zampanolide and epothilone A. Both compounds were bound to the taxane pocket of  $\beta$ -tubulin and used their respective side chains to induce structuring of the M-loop into a short helix. Because the M-loop establishes lateral tubulin contacts in microtubules, these findings explain how taxane-site MSAs promote microtubule assembly and stability. Further, our results offer fundamental structural insights into the control mechanisms of microtubule dynamics.

The binding of microtubule-stabilizing agents (MSAs) such as paclitaxel (Taxol, Bristol-Myers Squibb) to microtubules is generally thought to shift the assembly equilibrium of tubulin toward the polymeric state and to block cell entry into mitosis by suppressing microtubule dynamics (1, 2). However, MSAs are also known to induce microtubule polymerization under conditions in which tubulin does not assem-

ble spontaneously, suggesting a role in tubulin activation (3, 4). To provide insights into the interactions of MSAs with tubulin and microtubules at the molecular level, we crystallized the complex between  $\alpha\beta$ -tubulin (T), the stathmin-like protein RB3 (R), and tubulin tyrosine ligase (TTL) in the presence of either zampanolide (Zampa) or epothilone A (EpoA) (Fig. 1A) and determined the structures of the corresponding

protein-ligand complexes ( $T_2R$ -TTL-Zampa and  $T_2R$ -TTL-EpoA) at 1.8 and 2.3 Å resolution, respectively, by x-ray crystallography (fig. S1A and table S1) (5). The two tubulin heterodimers in the  $T_2R$ -TTL-MSA complexes were aligned in a head-to-tail fashion and assumed a curved conformation. Their overall structures superimposed well with the ones obtained in the absence of a MSA or of tubulin in complex with RB3 alone (6) [root mean square deviation (RMSD) ranging from 0.1 to 0.6 Å over more than 650 C $\alpha$  atoms], which suggests that the binding of MSAs and TTL does not induce major structural changes in the  $T_2R$  complex. Both Zampa and EpoA were deeply buried in a pocket formed by predominantly hydrophobic residues of helix H7;  $\beta$  strand S7; and the loops H6-H7, S7-H9 [designated the M-loop (7)], and S9-S10 of  $\beta$ -tubulin—this pocket is commonly known as the taxane pocket (Fig. 1, B to D) (8, 9).

<sup>1</sup>Biomolecular Research, Paul Scherrer Institut, Villigen PSI, Switzerland. <sup>2</sup>Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zürich, Zürich, Switzerland. <sup>3</sup>Centre for Biodiscovery, Victoria University of Wellington, Wellington, New Zealand. <sup>4</sup>Chemical and Physical Biology, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas CIB-CSIC, Madrid, Spain.

\*To whom correspondence should be addressed. E-mail: michel.steinmetz@psi.ch